Fundamental and clinical studies on ceftazidime in otitis media.

概要

論文の詳細を見る
Fundamental and clinical studies were performed to evaluate the usefulness of the injectable cephem antibiotic ceftazidime (CAZ, Modacin®) in the treatment of otitis media.1) In the fundamental studies, CAZ 1 or 2g was administered intravenously, and the concentration of CAZ in secretions from the middle ear was measured. The concentration 1 hour to 2 hours and 40 minutes after injection was 3.2-25.6μg/ml, and the penetration rate was 11.2-79.9% of the plasma concentration.2) In the clinical studies, CAZ 1 or 2g administered intravenously to 29 patients once or twice a day. The clinical efficacy rates were 75.0% (18/24) for suppurative otitis media, and 40.0% (2/5) for otitis media cholesteatoma. Bacteriological studies showed an elimination rate of 69.4% (25/36).3) No side effects were noted except for slight GPT elevation in one patient.4) The above results indicate that CAZ is a very useful antibiotic, especially for suppurative otitis media.